Galectin Therapeutics Inc. Share Price & Technical Analysis
GALT · $2.97 (+18.80%)
Healthcare / Biotechnology
$2.97
+18.80%
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company's lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhosi…
Price chart
Seasonality
May has 1 positive and 4 negative years (last 5 years shown)
9% return in May, -14% avg return in past 3 year May month.
-42% return in 2026, 80% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -33% | 7% | -7% | -18% | 9% | – | – | – | – | – | – | – | -42% |
| 25 | -8% | 33% | -25% | 17% | -7% | 62% | 71% | 19% | -2% | 38% | 0% | -28% | 171% |
| 24 | 0% | 18% | 20% | 46% | -23% | -15% | 9% | 8% | 8% | -11% | 16% | -57% | 19% |
| 23 | 0% | 75% | -5% | -14% | -11% | -12% | 7% | 13% | 12% | 0% | 0% | -15% | 49% |
| 22 | -10% | -5% | -16% | -6% | -13% | 0% | 77% | -17% | -11% | -18% | -7% | -15% | -42% |
Monthly return % by calendar month · historical pattern, not a forecast
Bullish · Downtrend · Strong
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company's lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhosis and portal hypertension. It has a joint venture co-owned by SBH Sciences, Inc. to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$146.80M
P/E ratio
—
52W high
$7.13
52W low
$1.22
Volume
5,07,886
Beta
0.45
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Galectin Therapeutics Inc. share price today?
- Galectin Therapeutics Inc. (GALT) last traded around $2.97 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does GALT have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for GALT. Download the app for real-time alerts.
- How can I analyze Galectin Therapeutics Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.